Dongkook Pharmaceutical Co Ltd

Dongkook Pharmaceutical maintains a strong liquidity position, with a current ratio of 2.11 and free cash flow of 50,189,569,340 KRW, indicating the company has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which introduces a medium liquidity risk. The debt-to-equity ratio of 0.11 suggests a conservative capital structure, with limited leverage exposure. In terms of profitability, the company's return on equity (ROE) of 9.95% and return on assets (ROA) of 6.21% are in line with industry norms, but do not exceed the median for the pharmaceutical sector. The operating margin of 10.21% (calculated from operating income of 94,705,612,170 KRW and revenue of 926,883,701,820 KRW) is also within the expected range for a mid-sized pharmaceutical firm. The company's revenue is primarily concentrated in South Korea, with no significant international exposure disclosed in the available data. This geographic concentration may limit growth opportunities and increase vulnerability to domestic regulatory or economic shifts. No specific segment breakdown is available, but the company operates as a single business unit focused on pharmaceuticals. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The capital expenditure of -45,996,274,360 KRW indicates a reduction in investment, which may signal a focus on cost control or a shift in strategic priorities. The risk assessment highlights a low dilution risk, with no near-term pressure from share issuance or dilutive events. The company's liquidity risk is rated as medium, primarily due to the negative net cash position after debt. Credit risk remains low, supported by a strong equity base and manageable debt levels. Recent investor relations data shows a mean price target of 37,500 KRW per share, with a median of 37,500 KRW and a high of 45,000 KRW. Analysts have issued one strong-buy and one buy recommendation, with no hold or sell ratings, indicating a generally positive outlook.